Context Therapeutics Inc Total Liabilities
Context Therapeutics Inc total liabilities. Based on the latest financial reports, Context Therapeutics Inc (CNTX) has total liabilities worth $7.96 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CNTX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Context Therapeutics Inc (2016–2025)
Total liabilities of Context Therapeutics Inc from 2016 to 2025. This chart illustrates how Context Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Context Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Context Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kwang Jin Ind. Co. Ltd
KQ:026910
|
Korea | ₩78.45 Billion |
|
TEKMAR GROUP PLC LS-01
F:6UA
|
Germany | €17.64 Million |
|
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
|
USA | $6.79 Million |
|
BMG Resources Ltd
AU:BMG
|
Australia | AU$76.70K |
|
Libet S.A.
WAR:LBT
|
Poland | zł22.31 Million |
|
Shin Poong Pap
KO:002870
|
Korea | ₩2.05 Billion |
|
Alphawave IP Group PLC
LSE:AWE
|
UK | GBX657.59 Million |
|
Hanil Chemical Ind. Co. Ltd
KQ:007770
|
Korea | ₩49.14 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Context Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Context Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Context Therapeutics Inc Total Liabilities Ratios Explained
Context Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Context Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Context Therapeutics Inc (2016–2025)
The table below shows the annual total liabilities of Context Therapeutics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.02 Million | +180.37% |
| 2024-12-31 | $2.86 Million | -31.76% |
| 2023-12-31 | $4.19 Million | +30.68% |
| 2022-12-31 | $3.21 Million | +5.74% |
| 2021-12-31 | $3.03 Million | -82.55% |
| 2020-12-31 | $17.39 Million | -28.25% |
| 2019-12-31 | $24.23 Million | +158.22% |
| 2017-12-31 | $9.38 Million | -13.83% |
| 2016-12-31 | $10.89 Million | -- |
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the de… Read more